Angiotensin II receptor antagonists (AT1 blockers, ARBs, sartans): Similarities and differences

Netherlands Heart Journal

Volumn 14, Issue 11, 2006, Pages 381-387

  Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiotensin II receptor antagonists; AT1 receptors; Insulin sensitisation; Renin angiotensin system

Indexed keywords

2 BUTYL 4 CHLORO 1 (2 CHLOROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 (2 NITROBENZYL) 5 IMIDAZOLEACETIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; GLITAZONE DERIVATIVE; INSULIN; IRBESARTAN; KINZAL; LOSARTAN; OLMESARTAN; PIOGLITAZONE; PRODRUG; RENIN INHIBITOR; ROSIGLITAZONE; SARALASIN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BINDING AFFINITY; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART FAILURE; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPERTENSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33947130913     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Goodfriend TL, Elliot ME, Can KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
2. Johnston CI. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens 1992;10:S13-26.
3. Peach MJ, Dostal DE. The angiotensin II receptor and the actions of angiotensin II. J Cardiovasc Pharmacol 1990;16:S25-30.
4. Gradman AH, Schmeider PR, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8.
5. Streeten DHP. Outpatient experience with saralasin. Kidney Int 1979;159(Suppl 9):44-52.
6. Timmermans PBMWM, Wong PC, Chin AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
7. Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997;15(Suppl 8):3-6.
8. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998;16(Suppl 17):3-9.
9. Wong PC, Chui AT, Price WA, et al. Non-peptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-2(2- chlorobenzyl)imidazole-5-acetic acid sodium salt (S8307). J Pharmacol Exp Ther 1988;247:1-10.
10. Baan J. Functional role of angiotensin II and AT1-receptor antagonists in human arteries and veins. PhD Thesis (ISBN 90-9011397-5), University of Amsterdam;1998:18.
11. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists. Am J Hypertens 1997;10:S306-10.
12. Unger T, Chung O, Csikos T, et al. Angiotensin receptors. J Hypertens 1996;14(Suppl):95-103.
13. 2-receptors. Eur J Pharmacol 1995;294:439-50.
14. Zhang J. Pharmacological effects of angiotensin II and non-peptidergic receptor antagonists. PhD Thesis (ISBN 90-9008377-4), University of Amsterdam 1995:145.
15. Zhang J, Pfaffendorf M, Zhang JS, van Zwieten PA. A non-competitive type of angiotensin II receptor antagonism by losartan in renal artery preparations. Eur J Pharmacol 1994;252:337-40.
16. Baan J, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Effects of losartan on vasoconstrictor responses to angiotensin II in the human forearm vascular bed of healthy volunteers. Cardiovasc Res 1996;32:973-9.
17. 1-subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265:826-34.
18. Shibouta Y, Inada Y, Ogima, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[2-(1H tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H benzimidazole-7-carboxylic acid (CV 11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy]-ethyl-2-ethoxy- 1-[[2-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-1H benzimidazole-7 carboxylate (TCY-116). J Pharmacol Exp Ther 1993;266:114-20.
19. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-912.
20. Dzielak DJ. Comparative pharmacology of the angiotensin II receptor antagonists. Exp Opin Invest Drugs 1998;7:741-51.
21. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995;333:1572.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
23. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL-study investigations. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
24. Pitt B, Segal R, Matinez FA, et al. On behalf of the ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet 1997;349:747-52.
25. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double blind intervention trial. J Hypertens 2003;21:875-86.
26. White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003;362:754-5.
27. Andersson OK, Neldman S. The anohypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure 1998;7:53-9.
28. 1-receptor blocker. J Hum Hypertens 1997;11(Suppl 2):1-95.
29. 1-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Auton Autacoid Pharmacol 2004;23:285-96.
30. McCellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713-8.
31. Parring HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
32. Lewis EJ, Huusicker LG, Clarke WR, et al. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
33. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997;54:885-902.
34. Man in 't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertension 1997;15(Suppl 7):27-33.
35. Brunner HR, Laers P. Clinical efficacy of olmesartan medoxomil. J Hyertens 2003;21(Suppl 2):543-6.
36. Unger T, McInnes GT, Neutel JM, Böhm M. The role of olmesartan medoxomil in the management of hypertension. Drugs 2004;64:2731-9.
37. Barnett AH, Bain SC, Bouter P, et al. Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
38. Benson SC, Perchadsingh HA, Ho CI, et al. Identification of telmisartan as an unique angiotensin II receptor antagonist with selective PPAR-γ modulating activity. Hypertension 2004;43:993-1002.
39. Schupp M, Janke J, Clasen R, Unger T, Kintschen U. Angiotensin type I receptor include peroxizome proliferator activated receptor-γ activity. Circulation 2004;109:2054-7.
40. Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005;19:173-83.
41. Julius S, Kjeldsen SE, Weber M, et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
42. Pfeffer MA, Mc Murray JJ, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
43. Viberti GC, Wheeldon MN. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
44. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-331.
45. Weber AM. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? J Renin Ang Ald Syst 2003;4:62-73.
46. Ruilope LM, Agabite Rosei E, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Pressure 2005;14:196-209.